Proteinacious intracellular aggregates in motor neurons are a key feature of both sporadic and familial amyotrophic lateral sclerosis (ALS). These inclusion bodies are often immunoreactive for Cu,Zn-superoxide dismutase (SOD1) and are implicated in the pathology of ALS. On the basis of this and a similar clinical presentation of symptoms in the familial (fALS) and sporadic forms of ALS, we sought to investigate the possibility that there exists a common disease-related aggregation pathway for fALS-associated mutant SODs and wild type SOD1. We have previously shown that oxidation of fALS-associated mutant SODs produces aggregates that have the same morphological, structural, and tinctorial features as those found in SOD1 inclusion bodies in ALS. Here, we show that oxidative damage of wild type SOD at physiological concentrations (ϳ40 M) results in destabilization and aggregation in vitro. Oxidation of either mutant or wild type SOD1 causes the enzyme to dissociate to monomers prior to aggregation. Only small changes in secondary and tertiary structure are associated with monomer formation. These results indicate a common aggregation prone monomeric intermediate for wild type and fALS-associated mutant SODs and provides a link between sporadic and familial ALS.
ALS1 is a fatal neurodegenerative disease that leads to the selective loss of motor neurons. Although ALS is predominately a sporadic disease, ϳ10% of cases are inherited in an autosomal dominant manner and a subset of these fALS cases are caused by mutations in the SOD1 gene (1). The gene product of SOD1, cytoplasmic Cu,Zn-superoxide dismutase (SOD1), is a ubiquitously expressed enzyme that catalyzes the disproportionation reaction of superoxide radicals (1). There are several lines of evidence that SOD1 mutations result in a gain, rather than loss of function that causes ALS. For instance, some fALS-associated mutant SOD1s retain full enzymatic activity (2). In addition, SOD1 knock-out mice lack ALS symptoms, whereas transgenic mice expressing the fALS-associated mutant G93A SOD1 develop ALS-like symptoms despite expression of endogenous mouse SOD1 (3). Lastly, overexpression of human wild type SOD1 fails to alleviate symptoms in this transgenic mouse model for ALS (3). One hypothesis of the gain of function of SOD1 is that misfolding of the mutant alters the catalytic mechanism to allow production of oxidants such as peroxynitrite (4) and possibly hydrogen peroxide (5). These reactive nitrogen and oxygen species cause toxicity by accumulated damage to proteins, nucleic acids, and lipids. Another major hypothesis is toxicity caused by intracellular aggregation of SOD1. SOD1 inclusion bodies, which also react with anti-ubiquitin antibodies, are a common pathological finding in motor neurons and neighboring astrocytes of ALS patients (6). These two hypotheses, however, are not mutually exclusive when considering that oxidative modification of proteins may contribute to aggregation and protease resistance. Protein aggregates are a common pathological feature...